Financiado en parte por Mochida Pharmaceutical Company
Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial
Tanaka K, Ishikawa Y, Yokoyama M, Origasa H, Matsuzaki M, Saito Y, Matsuzawa Y, Sasaki J, Oikawa S, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, JELIS Investigators, Japan
Stroke · 151 citas
Etiquetas de revisión
Financiado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiado por la industria
- Empresa
- Mochida Pharmaceutical Company
Según 1 financiador declarado.
Publicación
- Publicado
- 2008-05-04 · Stroke · vol. 39 · número 7 · págs. 2052–2058
- Editorial
- Lippincott Williams & Wilkins
- Citado
- 217 citas · más que el 99% de estudios similares · 10.8× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 39 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Lipoproteins and Cardiovascular Health · Acute Ischemic Stroke Management
- Palabras clave
- eicosapentaenoic acid, stroke recurrence, secondary stroke prevention, primary stroke prevention, hypercholesterolemia, statin therapy, omega-3 fatty acids, fish oil supplementation
- MeSH
- humans, hypercholesterolemia, recurrence, eicosapentaenoic acid, fatty acids, anticholesteremic agents, proportional hazards models, prospective studies, adult, aged, middle aged, female, male, stroke
17 autores
- Kortaro Tanaka🇯🇵Toyama University Hospital; University of Toyama; Kobe University
- Yuichi Ishikawa🇯🇵Toyama University Hospital; University of Toyama; Kobe University
- Mitsuhiro Yokoyama🇯🇵Toyama University Hospital; University of Toyama; Kobe University
- Hideki Origasa🇯🇵Toyama University Hospital; University of Toyama; Kobe University
- Masunori Matsuzaki🇯🇵Toyama University Hospital; University of Toyama; Kobe University
- Yasushi Saitō🇯🇵Toyama University Hospital; University of Toyama; Kobe University
- Yūji Matsuzawa🇯🇵Toyama University Hospital; University of Toyama; Kobe University
- Junichi Sasaki🇯🇵Toyama University Hospital; University of Toyama; Kobe University
- Shinichi Oikawa🇯🇵Toyama University Hospital; University of Toyama; Kobe University
- Hitoshi Hishida🇯🇵Toyama University Hospital; University of Toyama; Kobe University
- Hiroshige Itakura🇯🇵Toyama University Hospital; University of Toyama; Kobe University
- Toru Kita🇯🇵Toyama University Hospital; University of Toyama; Kobe University
- Akira Kitabatake🇯🇵Toyama University Hospital; University of Toyama; Kobe University
- Noriaki Nakaya🇯🇵Toyama University Hospital; University of Toyama; Kobe University
- Toshiie Sakata🇯🇵Toyama University Hospital; University of Toyama; Kobe University
- Kazuyuki Shimada🇯🇵Toyama University Hospital; University of Toyama; Kobe University
- Kunio Shirato🇯🇵Toyama University Hospital; University of Toyama; Kobe University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background and purpose
The JELIS trial examined the preventive effect of eicosapentaenoic acid (EPA) against coronary artery diseases. Hypercholesterolemic patients received statin only (no EPA group: n=9319) or statin with EPA (EPA group: n=9326) for around 5 years. EPA significantly suppressed the incidence of coronary events in previous analysis. Herein, we investigated the effects of EPA on the primary and secondary prevention of stroke.
Methods
We conducted a subanalysis of JELIS with respect to stroke incidence in the primary and secondary prevention subgroups defined as those without and with a prior history of stroke using Cox proportional hazard ratios, adjusted for baseline risk factor levels.
Results
As for primary prevention of stroke, this occurred in 114 (1.3%) of 8862 no EPA group and in 133 (1.5%) of 8841 EPA group. No statistically significant difference in total stroke incidence (Hazard Ratio, 1.08; 95% confidence interval, 0.95 to 1.22) was observed between the no EPA and the EPA groups. In the secondary prevention subgroup, stroke occurred in 48 (10.5%) of 457 no EPA group and in 33 (6.8%) of 485 EPA group, showing a 20% relative reduction in recurrent stroke in the EPA group (Hazard Ratio, 0.80; 95% confidence interval, 0.64 to 0.997).
Conclusions
Administration of highly purified EPA appeared to reduce the risk of recurrent stroke in a Japanese population of hypercholesterolemic patients receiving low-dose statin therapy. Further research is needed to determine whether similar benefits are found in other populations with lower levels of fish intake. The trial is registered at ClinicalTrials.gov (number NCT00231738).
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.